Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 23;15(12):e0244304.
doi: 10.1371/journal.pone.0244304. eCollection 2020.

Therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma using contrast-enhanced ultrasound: Focusing on inter-scanner, and inter-operator reproducibility

Hwaseong Ryu  1 , Jung Hoon Kim  2   3   4 , Seunghyun Lee  2   3 , Joon Koo Han  2   3   4
Affiliations

Therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma using contrast-enhanced ultrasound: Focusing on inter-scanner, and inter-operator reproducibility

Hwaseong Ryu et al. PLoS One. .

Abstract

Purpose: To assess therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma (HCC) using CEUS with focusing on inter-scanner and inter-operator reproducibility.

Materials and methods: For reproducibility, CEUS was performed using two different US scanners by two operators in sixteen rat models of HCC. Using perfusion analysis software (VueBox ®), eleven parameters were collected, and intra-class correlation coefficient (ICC) was used to analyze reproducibility. Then seventeen rat models of HCC were divided into treatment group (n = 8, 30 mg/kg/day sorafenib for five days) and control group (n = 9). CEUS was performed at baseline and 14 days after first treatment, and changes of perfusion parameters were analyzed.

Results: In treatment group, CEUS perfusion parameters showed a significant change. The peak enhancement (PE, 2.50 x103±1.68 x103 vs 5.55x102±4.65x102, p = 0.010) and wash-in and wash out AUC (WiWoAUC, 1.07x105±6.48 x104 vs 2.65x104±2.25x104, p = 0.009) had significantly decreased two weeks after treatment. On the contrary, control group did not show a significant change, including PE (1.15 x103±7.53x102 vs 9.43x102± 7.81 x102, p = 0.632) and WiWoAUC (5.09 x104±3.25x104 vs 5.92 x104±3.20x104, p = 0.646). For reproducibility, the various degrees of inter-scanner reproducibility were from poor to good (ICC: <0.01-0.63). However, inter-operator reproducibility of important perfusion parameters, including WiAUC, WoAUC, and WiWoAUC, ranged from fair to excellent (ICC: 0.59-0.93) in a different scanner.

Conclusion: Our results suggest that CEUS is useful for assessment of the treatment response after targeted therapy and with fair to excellent inter-operator reproducibility.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Outline of the experimental design.
Note–CEUS: contrast enhanced ultrasound examination. f/u: follow up.
Fig 2
Fig 2. Representative cases of CEUS examination of US scanner A (A, B, C) and US scanner B (D, E, F), demonstrating B-mode imaging (A, D), arterial phase (B, E), and delayed phase (C, F).
Note–CEUS: contrast enhanced ultrasound examination. Numbers in figure indicates time from contrast injection.
Fig 3
Fig 3. Representative case of CEUS image analysis using perfusion analysis software (VueBox ®), ROI manually drawn over tumor (A), and corresponding time-intensity curve profile (B).
Note–CEUS: contrast enhanced ultrasound examination. ROI: region of interest.
Fig 4
Fig 4. Representative cases of pathologic analysis, H&E (x40) (A and D), TUNEL (x400) (B and E), CD31 assay (x200) (C and F) of control group and sorafenib treated group.
Note–H&E: hematoxylin and eosin stain. TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick end-labelling staining.
See this image and copyright information in PMC

References

    1. Leen E, Averkiou M, Arditi M, Burns P, Bokor D, Gauthier T, et al. Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials. Eur Radiol. 2012;22(7):1442–50. Epub 2012/02/04. 10.1007/s00330-011-2373-2 . - DOI - PubMed
    1. Dizeux A, Payen T, Barrois G, Le Guillou Buffello D, Bridal SL. Reproducibility of Contrast-Enhanced Ultrasound in Mice with Controlled Injection. Mol Imaging Biol. 2016;18(5):651–8. Epub 2016/04/15. 10.1007/s11307-016-0952-y . - DOI - PubMed
    1. Guibal A, Taillade L, Mule S, Comperat E, Badachi Y, Golmard JL, et al. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy. Radiology. 2010;254(2):420–9. Epub 2010/01/23. 10.1148/radiol.09090728 . - DOI - PubMed
    1. Tang MX, Mulvana H, Gauthier T, Lim AK, Cosgrove DO, Eckersley RJ, et al. Quantitative contrast-enhanced ultrasound imaging: a review of sources of variability. Interface focus. 2011;1(4):520–39. Epub 2012/08/07. 10.1098/rsfs.2011.0026 - DOI - PMC - PubMed
    1. Lamuraglia M, Bridal SL, Santin M, Izzi G, Rixe O, Paradiso A, et al. Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. Crit Rev Oncol Hematol. 2010;73(3):202–12. Epub 2009/06/24. 10.1016/j.critrevonc.2009.06.001 . - DOI - PubMed

Publication types